Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SASOV: Surgery versus polidocanol sclerosis for labial venous malformations
2025-521374-34-00Phase 3Authorised
- Sponsor
- CHRU Tours
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of polidocanol in venous malformation (VM) (2 arms), sponsored by CHRU Tours. Primary endpoint: Overall effectiveness (primary). Planned start Aug 2026; status: authorised.
02
Drugs
polidocanol
03
Conditions
venous malformation (VM)
Beyond the preview
Go deeper on 2025-521374-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521374-34-00.